Valuation : Barinthus Biotherapeutics plc

Market Cap 30.49M 26.27M 24.63M 22.48M 42.36M 2.91B 42.49M 292M 114M 1.47B 114M 112M 4.88B P/E 2026 *
-0.8x
P/E 2027 * -0.7x
Enterprise Value 30.49M 26.27M 24.63M 22.48M 42.36M 2.91B 42.49M 292M 114M 1.47B 114M 112M 4.88B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99%
Yield 2026 *
-
Yield 2027 * -
08-06 Barinthus Biotherapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
04-30 Barinthus Biotherapeutics plc Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-22 Barinthus Biotherapeutics plc Appoints Douglas Swirsky as Chief Financial Officer, Effective as of May 1, 2026 CI
04-22 Barinthus Biotherapeutics plc Appoints Douglas Swirsky as Principal Accounting Officer, Effective as of May 1, 2026 CI
03-31 Barinthus Biotherapeutics plc Announces Step Down of Gemma Jones as Principal Accounting Officer, Effective April 30, 2026 CI
03-13 Barinthus Biotherapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2025 CI
12-10 Barinthus Bio announces update on phase 1 Avalon clinical trial of VTP-1000 for the treatment of celiac disease RE
12-10 Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease CI
11-07 Barinthus Biotherapeutics plc Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25-09-30 Barinthus Biotherapeutics plc and Clywedog Therapeutics, Inc Announces Executive and Board Changes CI
25-09-28 Clywedog Therapeutics, Inc. executed a letter of intent to acquire Barinthus Biotherapeutics plc from a group of shareholders in a reverse merger transaction. CI
25-08-07 Barinthus Biotherapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-06-12 European Equities Traded in the US as American Depositary Receipts Rise Thursday MT
1 day+2.07%
1 week+20.04%
Current month+33.79%
1 month+30.09%
3 months+9.64%
6 months+27.77%
Current year+6.60%
1 week 0.6
Extreme 0.6031
0.76
1 month 0.55
Extreme 0.55
0.76
Current year 0.51
Extreme 0.512
0.77
1 year 0.51
Extreme 0.512
1.83
3 years 0.51
Extreme 0.512
5.1
5 years 0.51
Extreme 0.512
16.5
10 years 0.51
Extreme 0.512
17.99
Manager TitleAgeSince
Chief Executive Officer 63 2019-07-31
Director of Finance/CFO 56 2026-04-30
Chief Tech/Sci/R&D Officer 68 2024-05-31
Director TitleAgeSince
Director/Board Member 63 2019-07-31
Chairman 62 2018-09-30
Director/Board Member 45 2019-12-31
Date Insider Type Main position Quantity % Market Cap.
6/10/25 Free

Director

20,174 0.0512%
6/10/25 Free

Chairman

20,174 0.0512%
6/10/25 Free

Director

20,174 0.0512%
Change 5-day change 1-year change 3-year change Capi.($)
+2.07%+20.04%-33.37%-62.68% 30.49M
-0.78%-1.42%+2.96%+21.65% 50.47B
-6.00%-0.75%+447.48%+535.14% 44.56B
-0.24%+0.74%+37.18%+16.26% 43.08B
-1.55%-2.07%+19.83%+71.70% 41.7B
-0.31%-0.83%+19.47%+48.24% 33.21B
-1.79%-3.24%+26.32%+125.06% 16.77B
-0.58%-2.12% - - 16.28B
-0.88%-0.66%+11.63%+27.62% 14.58B
-1.66%-1.25%+78.49%+42.97% 13.92B
Average -1.17%+1.05%+67.78%+91.77% 27.46B
Weighted average by Cap. -1.70%-1.06%+96.26%+129.01%

Financials

2026 *2027 *
Net sales - -
Net income -38.11M -32.84M -30.79M -28.11M -52.95M -3.64B -53.12M -365M -143M -1.84B -143M -140M -6.1B -44M -37.91M -35.55M -32.45M -61.13M -4.21B -61.33M -422M -165M -2.12B -165M -162M -7.04B
Net Debt - -
Logo Barinthus Biotherapeutics plc
Barinthus Biotherapeutics plc is a clinical-stage biopharmaceutical company focused on developing immunotherapeutic candidates for treating autoimmune and inflammatory diseases. The Company’s pipeline, built around platform technologies; viral vector-based, consists of ChAdOx and MVA, and synthetic, consisting of SNAP-Tolerance Immunotherapy (SNAP-TI). These platforms help to develop antigen-specific immunotherapeutic candidates designed to optimize the disease fighting capabilities of T cells. It is focused on developing two product candidates that harness its viral vector and synthetic platform technologies. These include VTP-300, a Phase II immunotherapeutic candidate designed as a potential component of a functional cure for chronic hepatitis B virus infection utilizing ChAdOx/MVA, and VTP-1000, its autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease. The Company's pipeline also includes VTP-850, VTP-500 and VTP-400.
Employees
14
Date Price Change Volume
26-08-28 US$0.7463 +2.07% 31,317
26-08-27 US$0.7312 +3.51% 78,803
26-08-26 US$0.7064 +7.03% 66,394
26-08-25 US$0.6600 +9.43% 47,197
26-08-24 US$0.6031 -2.99% 9,707
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.7463USD
Average target price
6.000USD
Spread / Average Target
+703.97%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BRNS Stock